Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1408889 | 0.80 | CYP1A2 (0.56) | NPC1RAB9APTGS1GAAHDAC2 | |
| SCHEMBL13647658 | 0.80 | GAA (0.60) | NPC1RAB9APTGS1GAAPOLB | |
| SCHEMBL9525322 | 0.79 | NPC1 (0.59) | NPC1RAB9APTGS1GAAPOLB | |
| SCHEMBL1273833 | 0.78 | GAA (0.70) | NPC1RAB9AGAAHDAC2POLB | |
| SCHEMBL13885541 | 0.78 | GAA (0.74) | NPC1RAB9APTGS1GAAPOLB | |
| SCHEMBL3919470 | 0.73 | RXFP1 (0.55) | PTGS1GAARXFP1 | |
| SCHEMBL3924697 | 0.72 | GAA (0.62) | NPC1RAB9APTGS1GAAPOLB | |
| SCHEMBL27685552 | 0.72 | POLB (0.53) | RAB9AGAAPOLBHPGDHDAC1 | |
| SCHEMBL15775220 | 0.71 | KDM4E (0.58) | NPC1RAB9APTGS1GAAP2RX1 | |
| SCHEMBL2564890 | 0.71 | NPC1 (1.00) | NPC1RAB9APTGS1POLBP2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| US-7384965-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-09-14 | — | — | US | disclosed |
| EP-1585726-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063155-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | PPARA, PPARG, PPARD | NPC1 2049/4885RAB9A 4004/4885PTGS1 1562/4885 |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | PPARA, PPARG, PPARD | NPC1 1797/4885RAB9A 3881/4885PTGS1 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.